Beacon Tx raised $75m in Series C led by Goldman Sachs Alternatives, joined by the RD Fund, Syncona, Forbion, Oxford Science Enterprises, and Advent.
29 December 2025
29 December 2025
Total investments received (USD): 366.25M
Round value (USD): 75M
Company: Beacon Therapeutics
Related deals
Immutrin in a £65M series A led by Frazier Life Sciences, joined by SR One, Qiming Venture Partners, Cambridge Enterprise Ventures and F-Prime
Investments
07 March 2026
R1 Therapeutics secured a $77.5 million Series A led by Abingworth, F-Prime Capital and DaVita Venture Group.
Investments
01 March 2026
Belgium
Austria
Germany
Switzerland
Denmark
Estonia
Finland
Iceland
Latvia
Lithuania
Norway
Sweden
France
Ireland
Italy
Portugal
Spain